Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Lung cancer save search
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
OptimizeRx Survey Addresses Treatment Selection, Discontinuation and Switching in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer – an Indication with Limited Patient Population
Published: 2021-12-15 (Crawled : 21:00) - globenewswire.com
OPRX | News A | $9.3 -0.53% -0.54% 300K
|
Technology Services
|
| O: 0.77%
H: 1.29%
C: -4.34%
treatment cel lung cancer positive cancer
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Published: 2021-11-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 14515.38%
H: 0.0%
C: -1.95%
fda lung cancer phase 1 positive cancer phase 2
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
Published: 2021-11-12 (Crawled : 15:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
treatment lung cancer positive results cancer research trial trial results
LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
ema lung cancer positive cancer chmp
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherapy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 14:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive therapy cancer conference plinabulin
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Published: 2021-10-20 (Crawled : 12:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.96%
H: 6.9%
C: -0.42%
treatment lung cancer positive cancer conference plinabulin
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
Published: 2021-10-15 (Crawled : 18:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.53%
H: 0.91%
C: 0.91%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.41%
H: 1.23%
C: 1.07%
lung cancer positive therapy cancer chmp
Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-09-20 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.78%
H: 11.36%
C: 3.1%
phase 2 lung cancer positive results cancer topline
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
Published: 2021-09-20 (Crawled : 12:00) - globenewswire.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: -19.1%
H: 7.65%
C: -16.07%
lung cancer europe positive cancer phase 3 plinabulin
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BPMC | News | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
treatment lung cancer positive cancer chmp
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.47%
H: 0.07%
C: -1.4%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.31%
H: 0.49%
C: -0.86%
treatment lung cancer positive results cancer conference
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-19 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.92%
H: 2.37%
C: 1.48%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.27%
H: 8.73%
C: 1.47%
treatment lung cancer positive therapy results cancer phase 3 trial
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-18 (Crawled : 23:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.92%
H: 2.37%
C: 1.48%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.27%
H: 8.73%
C: 1.47%
treatment lung cancer positive therapy results cancer phase 3 trial
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.57%
H: 5.08%
C: -6.62%
lung cancer gene therapy positive therapy cancer collaboration preclinical pre-clinical
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.